Silgard
human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)
Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)
Keep this leaflet. You may need to read it again.
If you have any further questions, please ask your doctor or pharmacist.
If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. See section 4.
What Silgard is and what it is used for
What you need to know before you receive Silgard
How Silgard is given
Possible side effects
How to store Silgard
Contents of the pack and other information
Silgard is a vaccine. Vaccination with Silgard is intended to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, and 18.
Medicinal product no longer authorised
These diseases include pre-cancerous lesions of the female genitals (cervix, vulva, and vagina); pre- cancerous lesions of the anus and genital warts in males and females; cervical and anal cancers. HPV types 16 and 18 are responsible for approximately 70% of cervical cancer cases, 75-80% of anal cancer cases; 70% of HPV-related pre-cancerous lesions of the vulva and vagina; 75% of HPV related pre-cancerous lesions of the anus. HPV types 6 and 11 are responsible for approximately 90% of genital wart cases.
Silgard is intended to prevent these diseases. The vaccine is not used to treat HPV related diseases. Silgard does not have any effect in individuals who already have a persistent infection or disease associated with any of the HPV types in the vaccine. However, in individuals who are already infected with one or more of the vaccine HPV types, Silgard can still protect against diseases associated with the other HPV types in the vaccine.
Silgard cannot cause the diseases it protects against.
Silgard produces type-specific antibodies and has been shown in clinical trials to prevent HPV 6-, 11-, 16-, and 18-related diseases in women 16-45 years of age and in men 16-26 years of age. The vaccine also produces type-specific antibodies in 9- to 15-year-old children and adolescents.
Silgard should be used in accordance with official guidelines.
you or your child is allergic (hypersensitive) to any of the active substances or any of the other ingredients of Silgard (listed under “other ingredients”– see section 6).
you or your child developed an allergic reaction after receiving a dose of Silgard.
you or your child suffer from an illness with high fever. However, a mild fever or upper respiratory infection (for example cold) itself is not a reason to delay vaccination.
Talk to your doctor, pharmacist or nurse before vaccination if you or your child
has a bleeding disorder (a disease that makes you bleed more than normal), for example haemophilia
has a weakened immune system, for example due to a genetic defect, HIV infection or medicines that affect the immune system.
Fainting, sometimes accompanied by falling, can occur (mostly in adolescents) following any needle injection. Therefore tell the doctor or nurse if you fainted with a previous injection.
As with any vaccine, Silgard may not fully protect 100% of those who get the vaccine. Silgard will not protect against every type of Human Papillomavirus. Therefore appropriate
precautions against sexually transmitted disease should continue to be used.
Silgard will not protect against other diseases that are not caused by Human Papillomavirus. Vaccination is not a substitute for routine cervical screening. You should continue to follow your
doctor’s advice on cervical smear/Pap tests and preventative and protective measures.
What other important information should you or your child know about Silgard
The duration of protection is currently unknown. Longer term follow-up studies are ongoing to determine whether a booster dose is needed.
Medicinal product no longer authorised
Silgard can be given with a Hepatitis B vaccine or with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of
your body, e.g. the other arm or leg) during the same visit.
Silgard may not have an optimal effect if:
used with medicines that suppress the immune system.
In clinical trials, oral or other contraceptives (e.g. the pill) did not reduce the protection obtained by Silgard.
Please tell your doctor or pharmacist if you or your child are taking or have taken recently any other medicines, including medicines obtained without a prescription.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before taking this medicine.
Silgard may be given to women who are breast-feeding or intend to breast-feed.
No studies on the effects on the ability to drive and use machines have been performed.
Silgard is given as an injection by your doctor. Silgard is intended for adolescents and adults from 9 years of age onwards.
Ifyouarefrom9toandincluding13yearsofage
Silgard can be administered according to a 2-dose schedule:
First injection: at chosen date
Second injection: 6 months after first injection
If the second vaccine dose is administered earlier than 6 months after the first dose, a third dose should always be administered.
Alternatively, Silgard can be administered according to a 3-dose schedule:
First injection: at chosen date
Second injection: 2 months after first injection
Third injection: 6 months after first injection
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.
Ifyouarefrom14yearsofage
Silgard should be administered according to a 3-dose schedule:
First injection: at chosen date
Second injection: 2 months after first injection
Third injection: 6 months after first injection
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period. Please speak to your doctor for more information.
Medicinal product no longer authorised
It is recommended that individuals who receive a first dose of Silgard complete the vaccination course with Silgard.
Silgard will be given as an injection through the skin into the muscle (preferably the muscle of the upper arm or thigh).
The vaccine should not be mixed in the same syringe with any other vaccines and solutions.
If you miss a scheduled injection, your doctor will decide when to give the missed dose.
It is important that you follow the instructions of your doctor or nurse regarding return visits for the follow-up doses. If you forget or are not able to go back to your doctor at the scheduled time, ask your
doctor for advice. When Silgard is given as your first dose, the completion of the vaccination course
should be done with Silgard, and not with another HPV vaccine.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all vaccines and medicines, Silgard can cause side effects, although not everybody gets them. The following side effects can be seen after the use of Silgard:
Very commonly (more than 1 in 10 patients), side effects found at the injection site include: pain, swelling and redness. Headache was also seen.
Commonly (more than 1 in 100 patients), side effects found at the injection site include: bruising, itching, pain in extremity. Fever and nausea have also been reported.
Rarely (less than 1 in 1000 patients): hives (urticaria).
Very rarely (less than 1 in 10,000 patients), difficulty breathing (bronchospasm) has been reported.
When Silgard was given with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine during the same visit, there was more headache and injection-site swelling.
Side effects that have been reported during marketed use include:
Fainting, sometimes accompanied by shaking or stiffening, has been reported. Although fainting episodes are uncommon, patients should be observed for 15 minutes after they receive HPV vaccine.
Allergic reactions that may include difficulty breathing, wheezing (bronchospasm), hives and rash have been reported. Some of these reactions have been severe.
As with other vaccines, side effects that have been reported during general use include: swollen glands (neck, armpit, or groin); muscle weakness, abnormal sensations, tingling in the arms, legs and upper body, or confusion (Guillain-Barré Syndrome, acute disseminated encephalomyelitis); dizziness, vomiting, joint pain, aching muscles, unusual tiredness or weakness, chills, generally feeling unwell, bleeding or bruising more easily than normal, and skin infection at the injection site.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects
not listed in this leaflet. You can also report side effects directly via thenationalreportingsystem
listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Medicinal product no longer authorised
Keep this vaccine out of the sight and reach of children.
Do not use this vaccine after the expiry date which is stated on the vial label and the outer carton (after EXP). The expiry date refers to the last day of that month.
Store in a refrigerator (2ºC - 8ºC). Do not freeze.
Keep the vial in the outer carton in order to protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
The active substances are: highly purified non-infectious protein for each of the Human
Papillomavirus types (6, 11, 16, and 18).
1 dose (0.5 ml) contains approximately:
Human Papillomavirus1 Type 6 L1 protein2,3 20 micrograms Human Papillomavirus1 Type 11 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 16 L1 protein2,3 40 micrograms Human Papillomavirus1 Type 18 L1 protein2,3 20 micrograms
1Human Papillomavirus = HPV
2L1 protein in the form of virus like particles produced in yeast cells (Saccharomyces cerevisiae
CANADE 3C-5 (Strain 1895)) by recombinant DNA technology.
3adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (0.225 milligrams Al). The other ingredients in the vaccine suspension are:
Sodium chloride, L-histidine, polysorbate 80, sodium borate and water for injections.
1 dose of Silgard suspension for injection contains 0.5 ml.
Prior to agitation, Silgard may appear as a clear liquid with a white precipitate. After thorough agitation, it is a white, cloudy liquid.
Silgard is available in packs of 1, 10 or 20 vials. Not all pack sizes are marketed.
MarketingAuthorisationHolder Merck Sharp and Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU
United Kingdom
Manufacturer
Merck Sharp & Dohme BV Waarderweg 39
Medicinal product no longer authorised
2031 BN Haarlem The Netherlands
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.
UAB Merck Sharp & Dohme
Tel. + 370 5 278 02 47
Мерк Шарп и Доум България ЕООД
Тел.: +359 2 819 3737
Merck Sharp & Dohme s.r.o.
Tel: +420 233 010 111
MSD Pharma Hungary Kft.
Tel.: +36 1 888 5300
MSD Danmark ApS
Tlf: + 45 4482 4000
Merck Sharp & Dohme Cyprus Limited
Tel: 8007 4433 (+356 99917558)
MSD SHARP & DOHME GMBH
Tel: 0800 673 673 673 (+49 (0) 89 4561 2612)
Merck Sharp & Dohme BV Tel: 0800 9999000
(+31 23 5153153)
Merck Sharp & Dohme OÜ
Tel.: +372 6144 200
MSD (Norge) AS
Tlf: +47 32 20 73 00
MSD Α.Φ.Β.Ε.Ε.
Τηλ: +30 210 98 97 300
Merck Sharp & Dohme Ges.m.b.H.
Tel: +43 (0) 1 26 044
Merck Sharp & Dohme de España, S.A.
Tel: +34 91 321 06 00
MSD Polska Sp. z o.o.
Tel: +48 22 549 51 00
MSD France
Tél: + 33 (0) 1 80 46 40 40
Merck Sharp & Dohme, Lda
Tel: +351 21 4465700
Medicinal product no longer authorised
Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333
Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00
Merck Sharp & Dohme Ireland (Human Health) Limited
Tel: +353 (0)1 2998700
Merck Sharp & Dohme, inovativna zdravila d.o.o.
Tel: +386 1 5204 201
MSD Danmark ApS
Tlf: + 45 4482 4000
Merck Sharp & Dohme, s. r. o.
Tel: +421 2 58282010
MSD Italia S.r.l.
Tel: +39 06 361911
medicalinformation.it@merck.com
MSD Finland Oy
Puh/Tel: +358 (0)9 804 650
Merck Sharp & Dohme Cyprus Limited
Τηλ.: 800 00 673 (+357 22866700)
Merck Sharp & Dohme (Sweden) AB
Tel: +46 77 5700488
SIA Merck Sharp & Dohme Latvija
Tel: + 371 67364224
Merck Sharp & Dohme Limited
Tel: +44 (0) 1992 467272
medicalinformationuk@merck.com
------------------------------------------------------------------------------------------------------------------------
The vaccine should be used as supplied; no dilution or reconstitution is necessary. The full recommended dose of the vaccine should be used. Any unused product or waste material should be disposed of in accordance with local requirements.
Shakewellbeforeuse. Thorough agitation immediately before administration is necessary to maintain suspension of the vaccine.
Medicinal product no longer authorised
Parenteral drug products should be inspected visually for particulate matter and discolouration prior to administration. Discard the product if particulates are present or if it appears discoloured.
Medicinal product no longer authorised